Northern Trust Corp Boosts Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Northern Trust Corp grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 613,170 shares of the company's stock after purchasing an additional 29,808 shares during the period. Northern Trust Corp owned about 1.28% of Amphastar Pharmaceuticals worth $22,767,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in AMPH. Barclays PLC boosted its stake in shares of Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after purchasing an additional 25,878 shares in the last quarter. Arkadios Wealth Advisors boosted its position in Amphastar Pharmaceuticals by 5.2% during the 4th quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company's stock worth $1,038,000 after buying an additional 1,379 shares during the period. Dakota Wealth Management boosted its position in Amphastar Pharmaceuticals by 31.7% during the 4th quarter. Dakota Wealth Management now owns 5,486 shares of the company's stock worth $204,000 after buying an additional 1,322 shares during the period. KBC Group NV boosted its position in Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after buying an additional 650 shares during the period. Finally, Pacer Advisors Inc. boosted its position in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after buying an additional 1,347,775 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMPH has been the topic of several recent research reports. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Wells Fargo & Company lowered their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Finally, Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ:AMPH traded up $0.54 during mid-day trading on Friday, hitting $24.86. The company had a trading volume of 510,253 shares, compared to its average volume of 478,104. The firm has a fifty day moving average price of $25.43 and a 200 day moving average price of $33.72. The company has a market capitalization of $1.18 billion, a PE ratio of 8.29, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96.

Insider Activity

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 5,231 shares of company stock worth $142,752 in the last quarter. 27.50% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.